Subscribe To

Price Alert Latest News Economic Calendar News

PROF / Profound Medical Corp. (PROF) CEO Dr. Arun Menawat on Q1 2022 Results - Earnings Call Transcript

Profound Medical Corp. (NASDAQ:PROF ) Q1 2022 Earnings Conference Call May 9, 2022 4:30 PM ET Company Participants Dr. Arun Menawat – Chief Executive Officer and Chairman of the Board Rashed Dewan – Chief Financial Officer Stephen Kilmer – Investor Relations Conference Call Participants Rahul Sarugaser – Raymond James Frank Takkinen – Lake Street Capital Markets Josh Jeggings – Cowen and Company Scott McAuley – Paradigm Capital Brian Gagnon – Gagnon Securities Operator Good day, and thank you for standing by. Welcome to the Profound Medical First Quarter 2022 Financial Results Conference Call. Read More

Demo Live Account See Partner Details

Content Topics

Profound

Medical

Corp

PROF

Arun

Menawat

2022

Results

prof

Earnings

Transcript

Stock

Posted: May 9 2022, 21:02

Author Name: Seeking Alpha

PROF News

By Seeking Alpha
November 4, 2023

Profound Medical Corp. (PROF) Q3 2023 Earnings Call Transcript

Profound Medical Corp. (NASDAQ:PROF ) Q3 2023 Earnings Conference Call November 2, 2023 4:30 PM ET Company Participants Stephen Kilmer - IR Arun Menaw

By GlobeNewsWire
October 19, 2023

Profound Medical to Release Third Quarter 2023 Financial Results on November 2 – Conference Call to Follow

TORONTO, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage med

By GlobeNewsWire
September 19, 2023

Profound Medical to Participate in the 2023 Cantor Global Healthcare Conference

TORONTO, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage me

By Zacks Investment Research
September 19, 2023

Strength Seen in Profound Medical (PROF): Can Its 19.5% Jump Turn into More Strength?

Profound Medical (PROF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions

By Seeking Alpha
August 9, 2023

Profound Medical Corp. (PROF) Q2 2023 Earnings Call Transcript

Profound Medical Corp. (NASDAQ:PROF ) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants Stephen Kilmer - IR Arun Menawat

By Zacks Investment Research
August 9, 2023

Profound Medical (PROF) Reports Q2 Loss, Misses Revenue Estimates

Profound Medical (PROF) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to los

By GlobeNewsWire
August 2, 2023

Profound Medical to Release Second Quarter 2023 Financial Results on August 9 – Conference Call to Follow

TORONTO, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage med

By Seeking Alpha
June 22, 2023

Profound Medical: TULSA-PRO Now Selling, Recurring Revenues Up 43%

Profound Medical Corp's TULSA-PRO system has the potential to disrupt the surgical treatment of prostate disease. The company is delivering solid grow

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.